Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT05815927
Title	Pembrolizumab and Radiotherapy for Oligometastatic Head and Neck Cancer (PROLoNg)
Acronym	PROLoNg
Recruitment	Not yet recruiting
Gender	both
Phase	Phase III
Variant Requirements	Yes
Sponsors	European Organisation for Research and Treatment of Cancer - EORTC
Indications	hypopharynx cancer oropharynx cancer head and neck squamous cell carcinoma oral cavity cancer laryngeal squamous cell carcinoma
Therapies	Pembrolizumab
Age Groups:	adult \| senior
Covered Countries	ITA \| ESP \| CHE \| BEL